Wells Fargo
VRCA icon

Wells Fargo’s Verrica Pharmaceuticals VRCA Stock Holding History

Wells Fargo’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-493
Closed -$2.61K – 7420
2025
Q2 		$2.61K Sell
493
-1,438
-74% -$7.74K ﹤0.01% 6180
2025
Q1 		$8.54K Buy
1,931
+1,046
+118% +$6.76K ﹤0.01% 5923
2024
Q4 		$6.19K Buy
885
+302
+52% +$3.32K ﹤0.01% 6027
2024
Q3 		$8.46K Sell
583
-23
-4% -$1.04K ﹤0.01% 5834
2024
Q2 		$44.2K Sell
606
-168
-22% -$12.9K ﹤0.01% 5349
2024
Q1 		$45.8K Sell
774
-216
-22% -$11.9K ﹤0.01% 5292
2023
Q4 		$72.5K Buy
990
+423
+75% +$17.4K ﹤0.01% 5100
2023
Q3 		$22K Sell
567
-453
-44% -$23K ﹤0.01% 5558
2023
Q2 		$58.8K Buy
1,020
+857
+526% +$52K ﹤0.01% 5352
2023
Q1 		$10.6K Hold
163
– – ﹤0.01% 5844
2022
Q4 		$4.47K Buy
163
+1
+0.6% +$27 ﹤0.01% 5808
2022
Q3 		$4K Buy
162
+104
+179% +$3.56K ﹤0.01% 5992
2022
Q2 		$1K Sell
58
-541
-90% -$27.2K ﹤0.01% 6629
2022
Q1 		$48K Sell
599
-440
-42% -$36.3K ﹤0.01% 5681
2021
Q4 		$96K Sell
1,039
-1,034
-50% -$117K ﹤0.01% 5665
2021
Q3 		$259K Buy
2,073
+2,020
+3,811% +$227K ﹤0.01% 4993
2021
Q2 		$6K Sell
53
-377
-88% -$45.7K ﹤0.01% 6300
2021
Q1 		$65K Sell
430
-893
-67% -$124K ﹤0.01% 5688
2020
Q4 		$152K Buy
1,323
+235
+22% +$21.6K ﹤0.01% 5197
2020
Q3 		$85K Sell
1,088
-213
-16% -$17.4K ﹤0.01% 5324
2020
Q2 		$143K Buy
1,301
+55
+4% +$6.36K ﹤0.01% 5064
2020
Q1 		$136K Sell
1,246
-835
-40% -$110K ﹤0.01% 4906
2019
Q4 		$330K Sell
2,081
-281
-12% -$41.5K ﹤0.01% 4677
2019
Q3 		$348K Buy
2,362
+109
+5% +$12.1K ﹤0.01% 4614
2019
Q2 		$262K Buy
2,253
+1,956
+659% +$183K ﹤0.01% 4817
2019
Q1 		$32K Hold
297
– – ﹤0.01% 5422
2018
Q4 		$24K Buy
297
+215
+262% +$26.1K ﹤0.01% 5730
2018
Q3 		$13K Buy
+82
New +$14K ﹤0.01% 5938

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return

Wells Fargo's VRCA Position: Q3 2025 in Review

Wells Fargo sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 493 shares — an estimated $2.61K sold.

Wells Fargo first reported a position in VRCA in Q3 2018 and held it in 28 quarters. The position peaked at $348K in Q3 2019. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • Wells Fargo reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Wells Fargo sold 493 Verrica Pharmaceuticals shares in Q3 2025, an estimated $2.61K.
  • Wells Fargo first reported a position in Verrica Pharmaceuticals in Q3 2018 and held it in 28 quarters.
  • Wells Fargo's Verrica Pharmaceuticals position peaked at $348K in Q3 2019.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.